Criteria adopted in different models of public healthcare systems for the evaluation of reimbursement recommendations of orphan drugs: a scoping review.
Introdução: Access to drugs for rare diseases constitutes a challenge to healthcare systems, especially those with public funding. The difficulty of conducting robust clinical trials limits the quality of evidence and elevates the cost of development, later translated into the drug's prices. Th...
Saved in:
Main Authors: | Arturo Felippini (Author), Luiza Vasconcelos Biglia (Author), Tácio Mendonça Lima (Author), Patricia Melo Aguiar (Author) |
---|---|
Format: | Book |
Published: |
Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019) -
Análise das incorporações de medicamentos para doenças raras no Brasil: é possível acesso integral a esta minoria?
by: Luiza Vasconcelos Biglia, et al.
Published: (2023) -
Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023) -
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024) -
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
by: Krzysztof Piotr Malinowski, et al.
Published: (2019)